Applied behaviour analysis clinic Blue Sprig Pediatrics Inc revealed on Tuesday the completion of the acquisition of the assets of West Texas Autism Center in West Texas for an undisclosed amount.
Founded in 2012 by Dr Melissa Richardson, West Texas Autism Center is a clinic based provider of ABA therapy with a goal to help children with autism achieve their full potential and thereby enjoy lives that are as independent and fulfilling as possible.
With two clinics in Abilene, Texas and San Angelo, Texas, West Texas Autism Center is a clinic-based provider of Applied Behavior Analysis (ABA) therapy services treating children with Autism Spectrum Disorder (ASD).
Through the acquisition, BlueSprig's mission is to change the world for children with autism by providing the very best ABA services, investing in research to improve those services as well as advocating for resources and vital funding for children on the spectrum.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA